Peptide Comparison
IGF-1 DES vs PEG-MGF
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two IGF-1 analogs in the same regimen: Moderate-High risk per peptide research literature. Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks.
Data-derived verdict
IGF-1 DES has stronger documented evidence (Anecdotal + Animal Studies) than PEG-MGF (Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 DES is the safer pick. PEG-MGF may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| IGF-1 DES | PEG-MGF | |
|---|---|---|
| Class | IGF-1 analog (truncated); anabolic | Pegylated IGF-1 splice variant; anabolic |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity | PEG conjugation extends half-life of MGF for systemic action |
| Route | SC / IM | SC / IM |
| Half-life | ~30 min | ~2-3 days |
| Dosage (research) | 50-150 mcg SC near target muscle | 200-400 mcg SC 1-2x weekly |
| Evidence tier | Anecdotal + Animal Studies | Anecdotal |
| Research depth | 25 indexed | 1 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Hypoglycemia; localized tissue growth; theoretical cancer risk | Immunogenicity concerns with PEG; limited safety data |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick IGF-1 DES or PEG-MGF?
IGF-1 DES has stronger documented evidence (Anecdotal + Animal Studies) than PEG-MGF (Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 DES is the safer pick. PEG-MGF may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between IGF-1 DES and PEG-MGF?
IGF-1 DES is classed as IGF-1 analog (truncated); anabolic; PEG-MGF is classed as Pegylated IGF-1 splice variant; anabolic. Reported mechanism: IGF-1 DES, Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity; PEG-MGF, PEG conjugation extends half-life of MGF for systemic action. Reported half-life: IGF-1 DES, ~30 min; PEG-MGF, ~2-3 days. Routes in published studies: IGF-1 DES, SC / IM; PEG-MGF, SC / IM.
Which has stronger evidence, IGF-1 DES or PEG-MGF?
IGF-1 DES and PEG-MGF sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. IGF-1 DES is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 25 indexed studies. PEG-MGF is graded Anecdotal, with 1 cited source on its reference page and 1 indexed studies.
Which is more accessible, IGF-1 DES or PEG-MGF?
Neither IGF-1 DES nor PEG-MGF is an FDA-approved drug. Catalog status: IGF-1 DES, Research Chemical; PEG-MGF, Research Chemical. PEG-MGF's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are IGF-1 DES and PEG-MGF ever combined?
IGF-1 DES and PEG-MGF appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two IGF-1 analogs in the same regimen, moderate-high risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…